Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Abstract Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman
Formato:	Artigo
Idioma:	Inglês
Publicado:	Adis, Springer Healthcare 2024-09-01
Series:	Rheumatology and Therapy
Assuntos:	Disease activity Fatigue Guselkumab Joint disease Minimal clinically meaningful improvement Pain
Acceso en liña:	https://doi.org/10.1007/s40744-024-00702-0
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!